×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

New Glaxo orders point to big flu vaccine windfall

New Glaxo orders point to big flu vaccine windfall
Comment E-mail Print Share
First Published: Tue, Oct 06 2009. 03 06 PM IST
Updated: Tue, Oct 06 2009. 03 06 PM IST
London: GlaxoSmithKline Plc won a further 22 government orders for its H1N1 swine flu vaccine in the last two months, taking the total number of doses ordered to 440 million worth some $3.5 billion.
The Britain-based drugmaker said on Tuesday first supplies were being shipped to governments this week and deliveries would continue through both the fourth quarter of 2009 and the first half of 2010.
The addition of a further 149 million orders since 4 August, when Glaxo last gave an update, points to a substantial sales and profit windfall as a result of the swine flu pandemic.
Governments around the world are preparing to start mass immunisation programmes ahead of a feared second wave of infection as the northern hemisphere heads into winter.
Glaxo previously said it expects to sell its H1N1 vaccine for around the same price as seasonal flu shots, which fetch about five pounds ($7.96) a dose, implying its total booked orders are now worth some £2.2 billion ($3.5 billion).
It also has a variety of agreements in place with the US government to supply pandemic products worth an additional $250 million and discussions are continuing with various other governments for further vaccine supplies.
“The market may look through GSK’s pandemic sales as being a one-off,” Citigroup analyst Kevin Wilson said in a note.
“However, we believe that pandemic sales will lead to potential earnings surprises through the fourth quarter of 2009 to the second quarter of 2010 when overlaid on the rest of the business, which is now set to recover from US generic washouts.”
Shipments of H1N1 vaccine will be delivered in both the fourth quarter of 2009 and the first half of 2010, Glaxo said.
Rivals in flu vaccines include Sanofi-Aventis, Novartis, Baxter, AstraZeneca and CSL.
But Glaxo believes it has an edge because its vaccine uses a special adjuvant -- a substance designed to boost the immune response -- which means only a fraction of the normal amount of antigen, or active ingredient, is needed in each shot.
In addition to bumper vaccine revenue, Glaxo also stands to book extra sales of flu drug Relenza, a rival to Roche’s Tamiflu.
Shares in Glaxo were flat in a slightly weaker market for European drug stocks by 0845 GMT.
Comment E-mail Print Share
First Published: Tue, Oct 06 2009. 03 06 PM IST